Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Intervalo de año de publicación
1.
Semina cienc. biol. saude ; 34(2): 159-166, jul.-dez. 2013. tab
Artículo en Portugués | LILACS | ID: lil-726424

RESUMEN

Microesferas de liberação prolongada de diclofenaco de sódio (DFS) foram preparadas empregando o acetobutirato de celulose (ABC) para obtenção da matriz polimérica. Buscando modular a velocidade de liberação do fármaco, a adição de Poloxamer 188 na formulação foi testada, com diferentes proporções de ABC: Pluronic F68 (1:0; 9:1; 3:1 e 1:1). Com exceção da formulação contendo ABC e Pluronic F68 na proporção de 1:1, as outras formulações testadas conduziram à formação de partículas esféricas de tamanho micrométrico. Quando a misturaA BC: Pluronic F68 (1:1) foi empregada, ocorreu à precipitação de uma massa polimérica, sendo este efeito relacionado à elevada concentração do polímero hidrofílico na preparação. Quando comparado com as microesferas preparadas unicamente com ABC, o teor e a eficiência de encapsulação aumentaram com o acréscimo de Poloxamer 188 às formulações. Efeito semelhante foi observado na avaliação da velocidade de liberação do fármaco em meio tampão fosfato pH 7,5. Enquanto as microesferas preparadas apenas com ABC conduziram à liberação de 25% do fármaco encapsulado após 12 horas de ensaio, as microesferas preparadas com relação ABC:Pluronic 9:1 e 3:1 conduziram à liberação de 30% e 70% do fármaco, respectivamente.


Extended-release microspheres containing sodium diclofenac were prepared using the cellulose acetate butyrate (CAB) to obtain the polymer matrix. Looking modulate the rate of drug release, the addition of Poloxamer 188 at different concentrations into formulations was tested in order to obtain CAB to Poloxamer ratio of 1:0, 9:1, 3:1 and 1:1. Excepting for the formulation containing CAB and Poloxamer 1:1, the other formulations resulted in formation of spherical particles of micrometer size range. When the mixture CAB:Poloxamer (1:1) was employed, the precipitation of a polymeric mass occorred, and this effect was related to the high concentration of the hydrophilic polymer in the preparation. When compared to the microspheres prepared only with CAB, the drug content and the encapsulation efficiency increased with the addition of Poloxamer 188 in the formulations. A similar effect was observed in the evaluation of the rate of drug release in pH 7.5 phosphate buffer. While the microspheres prepared with CAB led to release of 25% of the encapsulated drug after 12 hours of testing, the microspheres prepared with CAB: Poloxamer 9:1 and 3:1 resulted in release of 30% and 70% of the drug, respectively.


Asunto(s)
Diclofenaco , Microesferas , Poloxámero
2.
Antimicrob Agents Chemother ; 56(5): 2259-67, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22330919

RESUMEN

Nanoenabled drug delivery systems against tuberculosis (TB) are thought to control pathogen replication by targeting antibiotics to infected tissues and phagocytes. However, whether nanoparticle (NP)-based carriers directly interact with Mycobacterium tuberculosis and how such drug delivery systems induce intracellular bacterial killing by macrophages is not defined. In the present study, we demonstrated that a highly hydrophobic citral-derived isoniazid analogue, termed JVA, significantly increases nanoencapsulation and inhibits M. tuberculosis growth by enhancing intracellular drug bioavailability. Importantly, confocal and atomic force microscopy analyses revealed that JVA-NPs associate with both intracellular M. tuberculosis and cell-free bacteria, indicating that NPs directly interact with the bacterium. Taken together, these data reveal a nanotechnology-based strategy that promotes antibiotic targeting into replicating extra- and intracellular mycobacteria, which could actively enhance chemotherapy during active TB.


Asunto(s)
Antituberculosos/farmacología , Isoniazida/análogos & derivados , Isoniazida/farmacología , Macrófagos/efectos de los fármacos , Mycobacterium tuberculosis/efectos de los fármacos , Nanopartículas , Animales , Disponibilidad Biológica , Células Cultivadas , Composición de Medicamentos , Sistemas de Liberación de Medicamentos/métodos , Concentración de Iones de Hidrógeno , Interacciones Hidrofóbicas e Hidrofílicas , Ácido Láctico/química , Macrófagos/microbiología , Ratones , Microscopía de Fuerza Atómica , Microscopía Confocal , Mycobacterium tuberculosis/fisiología , Tamaño de la Partícula , Fagocitosis , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Tuberculosis Pulmonar/tratamiento farmacológico , Tuberculosis Pulmonar/microbiología
3.
J Pharm Sci ; 98(12): 4844-51, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19455621

RESUMEN

Nanocarriers have been developed aiming at drug delivery; however, the irritating effects of these nanoparticles on naïve or inflamed articular tissues are not known. Poly(D,L-lactide) (N-PLA), methoxy poly(ethylene glycol)-b-poly(D,L-lactide) (N-PEG-PLA), and Dynasan 116 (SLN) were used to prepare the nanocarriers. The average diameter (nm) and zeta potential (mV) of these particles were, respectively, 251 and -33.2, 169 and -22.1, and 105 and -13.0. Naive or carrageenan-primed knee-joints received 100 microL of nanoparticle suspensions or control solution. Incapacitation and articular diameter were determined hourly. Synovial leukocytes were counted 6 h after nanoparticle injection. N-PLA increased the articular diameter and leukocytes, but did not cause incapacitation. In primed knee-joints, N-PLA caused incapacitation, and increased the articular diameter and leukocytes. SLN did not produce inflammatory signals either in naive or primed knees. In primed knee-joints, N-PEG-PLA presented an intermediate effect characterized by an increase in the articular diameter, and a slight increase of leukocytes, but not incapacitation. These results suggest that solid lipid nanoparticles may be safer than polymeric ones, which may be correlated to their chemical composition and superficial charge.


Asunto(s)
Analgésicos/farmacología , Portadores de Fármacos/toxicidad , Edema/inducido químicamente , Articulaciones/patología , Analgésicos/química , Animales , Carragenina , Movimiento Celular/efectos de los fármacos , Quimiotaxis de Leucocito/efectos de los fármacos , Portadores de Fármacos/química , Edema/patología , Electroquímica , Femenino , Miembro Posterior/patología , Nanopartículas , Nanoestructuras , Tamaño de la Partícula , Ratas , Ratas Wistar , Líquido Sinovial/citología , Líquido Sinovial/efectos de los fármacos
4.
J Pharm Pharm Sci ; 9(1): 22-31, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16849005

RESUMEN

PURPOSE: The aim of this work was to evaluate the pulmonary antimetastatic activity and the systemic toxicity of camptothecin-loaded microspheres. METHODS: PCL microspheres containing camptothecin (CPT) were prepared by the emulsion solvent/evaporation method and characterized according to their encapsulation efficiency, particle size, morphology, and drug release. The ability of CPT to inhibit the lung metastasis was verified using an experimental mouse model intravenously injected with metastatic B16- F10 melanoma cells. The microspheres and the free drug were given intraperitoneally at a dose of 7 mg/kg at intervals of three or five days for 24 days. The systemic toxicity of CPT was evaluated by weight measurements, survival and hemograms of the animals. RESULTS: The encapsulation efficiency was nearly 80%. The drug release was complete after 72 hours, but the burst effect increased from 7% to 35% with the increase in CPT content in the particles. It was observed during the in vivo essays that all groups treated with CPT had a decrease of nearly 70% in the number of lung metastases. However, systemic toxicity was verified in animals that received the free drug. CONCLUSION: Camptothecin-loaded microspheres demonstrated similar therapeutic efficacy when compared to those of the free drug, but the toxicity was significantly reduced.


Asunto(s)
Antineoplásicos Fitogénicos/administración & dosificación , Camptotecina/administración & dosificación , Sistemas de Liberación de Medicamentos , Melanoma/prevención & control , Metástasis de la Neoplasia/prevención & control , Animales , Antineoplásicos Fitogénicos/toxicidad , Camptotecina/toxicidad , Cápsulas , Preparaciones de Acción Retardada , Modelos Animales de Enfermedad , Portadores de Fármacos , Ratones , Microesferas , Trasplante de Neoplasias , Tamaño de la Partícula
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA